ArticleNature medicine2022
CAR T cells reach clinical milestone in prostate cancer.
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Bispecific antibodies in metastatic castration-resistant prostate cancer: therapeutic strategies and frontier advances.World journal of urology · 2025Review
- Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Targeted and immunotherapeutic strategies for castration-resistant prostate cancer: emerging strategies, challenges, and future directions.Frontiers in immunology · 2025Review
- T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.Cancer biology & therapy · 2024Review
- Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers.Nature reviews. Urology · 2024Review
- Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.Nature communications · 2023Article
- Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer.Journal for immunotherapy of cancer · 2023Article
- Progression in immunotherapy for advanced prostate cancer.Frontiers in oncology · 2023Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
35314844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.